{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:02:59Z","timestamp":1789984979831,"version":"4.0.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ketamine Assisted Psychotherapy (KAP) is a developing modality with broad impact on humans suffering with a variety of emotional and relationship difficulties that encompass many diagnostic entities. Our application of KAP has extended to and included the treatment of adolescents and young adults in a family therapy format. Given the increasing scope and complexity of the adolescent mental health crisis and the frequent failures to respond to conventional treatment, the promise of KAP deserves thorough investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We previously described the process of KAP in our adolescent population that included four case reports exemplifying our approach. Here we report on the longitudinal clinical experience of 19 adolescents and young adults (ages 14\u201324; mean age 19.3 \u00b1 3.1 years; 11 female, 7 male, 1 non-binary) who completed three or more KAP sessions at a single community outpatient clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BDI-II scores declined by an estimated 0.65 points per visit (95% CI: -0.90, -0.40) and HAM-A scores by 0.21 points per visit (95% CI: -0.44, +0.01), based on linear mixed-effects models. Approximately 63.2% of patients (12\/19) achieved medium or large individual treatment effects on BDI; 47.4% (9\/19) on HAM-A. Physician and patient reports indicated overall benefit in 68.4% of cases (13\/19), including marked reductions in suicidality in at-risk patients. Ketamine was well tolerated across 167 documented sessions; nausea was the only notable adverse event, occurring in 5.4% of sessions and largely manageable with standard antiemetics. No hospitalizations, substance misuse, or evidence of neurological harm occurred over a median individual follow-up of 5.6 months (mean 10.1, range 0.9-36.4 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings suggest that KAP is feasible and well tolerated in a diagnostically complex adolescent population, with clinically meaningful reductions in depression and a similar trend for anxiety associated with continued treatment. To our knowledge, this is the first report to provide longitudinal quantitative data for office-based KAP in adolescents and young adults, and it establishes a foundation for and supports the design of future controlled trials in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1886833","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:17:57Z","timestamp":1789982277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adults"],"prefix":"10.3389","volume":"17","author":[{"given":"Phil","family":"Wolfson","sequence":"first","affiliation":[{"name":"The Ketamine Research Foundation","place":["San Anselmo, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Carroll","sequence":"additional","affiliation":[{"name":"The Ketamine Research Foundation","place":["San Anselmo, CA, United States"]},{"name":"University of San Francisco","place":["San\u00a0Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1141988","article-title":"Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses","volume":"14","author":"Wolfson","year":"2023","journal-title":"Front Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1517533","article-title":"The youth mental health crisis: analysis and solutions","volume":"15","author":"McGorry","year":"2025","journal-title":"Front Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-070849","article-title":"The youth mental health crisis in the United States: epidemiology, contributors, and potential solutions","volume":"156","author":"Woolf","year":"2025","journal-title":"Pediatrics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.2482","article-title":"Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a meta-analysis","volume":"175","author":"Racine","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(01)01129-5","article-title":"Mood disorders in children and adolescents: an epidemiologic perspective","volume":"49","author":"Kessler","year":"2001","journal-title":"Biol Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.188.3.216","article-title":"Longitudinal investigation into childhood- and adolescence-onset depression: psychiatric outcome in early adulthood","volume":"188","author":"Dunn","year":"2006","journal-title":"Br J Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamapsychiatry.55","article-title":"Prevalence, correlates and treatment of lifetime suicidal behavior among adolescents: results from the National Comorbidity Survey Replication \u2013 Adolescent Supplement (NCS-A)","volume":"70","author":"Nock","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.2006.01615.x","article-title":"Adolescent suicide and suicidal behavior","volume":"47","author":"Bridge","year":"2006","journal-title":"J Child Psychol Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.06.015","article-title":"Societal burden of adolescent depression, an overview and cost-of-illness study","volume":"241","author":"Bodden","year":"2018","journal-title":"J Affect Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.09.021","article-title":"Prevalence and treatment of depression, anxiety, and conduct problems in US children","volume":"206","author":"Ghandour","year":"2019","journal-title":"J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.2360","article-title":"Clinical stage transitions in persons aged 12 to 25 years presenting to early intervention mental health services with anxiety, mood, and psychotic disorders","volume":"76","author":"Iorfino","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jad.2010.10.046","article-title":"Mental health outcome of long-term and episodic adolescent depression: 15-year follow-up of a community sample","volume":"130","author":"Jonsson","year":"2011","journal-title":"J Affect Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0077","article-title":"National patterns of commonly prescribed psychotropic medications to young people","volume":"28","author":"Sultan","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.13202","article-title":"Annual research review: defining and treating pediatric treatment-resistant depression","volume":"61","author":"Dwyer","year":"2020","journal-title":"J Child Psychol Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety, and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009\u2013January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J Affect Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J Psy. Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1209419","article-title":"Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective \u2013 a new and evolving approach","volume":"15","author":"Wolfson","year":"2024","journal-title":"Front Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067194","article-title":"Ketamine for the acute treatment of severe suicidal ideation: double blind, randomized placebo controlled trial","volume":"376","author":"Abbar","year":"2022","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am J Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2023.05.031","article-title":"Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial","volume":"63","author":"Zhou","year":"2024","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.02.058","article-title":"The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: a systematic review","volume":"137","author":"Di Vincenzo","year":"2021","journal-title":"J Psychiatr Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-020-01542-3","article-title":"A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders","volume":"30","author":"Kim","year":"2021","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0030","article-title":"Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study","volume":"28","author":"Cullen","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20010018","article-title":"Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial","volume":"178","author":"Dwyer","year":"2021","journal-title":"Am J Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-020-04542-z","article-title":"Brief report: intranasal ketamine in adolescents and young adults with autism spectrum disorder\u2014initial results of a randomized, controlled, crossover, pilot study","volume":"51","author":"Wink","year":"2021","journal-title":"J Autism Dev Disord"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1515\/ijdhd-2015-0003","article-title":"Ketamine and the core symptoms of autism","volume":"15","author":"Kastner","year":"2016","journal-title":"Int J Disabil Hum Dev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120928203","article-title":"Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: preliminary evidence in adolescents with treatment-resistant depression","volume":"35","author":"Roy","year":"2021","journal-title":"J Psychopharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1176\/appi.ajp-rj.2022.170401","article-title":"Ketamine for adolescent depression: an overview and considerations for future directions","volume":"17","author":"Baek","year":"2022","journal-title":"Am J Psychiatry Resid. J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-023-01432-w","article-title":"Ketamine use in child and adolescent psychiatry: emerging data in treatment-resistant depression, insights from adults, and future directions","volume":"25","author":"Ryan","year":"2023","journal-title":"Curr Psychiatry Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2023.0047","article-title":"Exploring predictors of ketamine response in adolescent treatment-resistant depression","volume":"34","author":"Lineham","year":"2024","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.12.097","article-title":"A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings","volume":"301","author":"McInnes","year":"2022","journal-title":"J\u00a0Affect Disord"},{"key":"B33","volume-title":"Ketamine for Depression","author":"Hyde","year":"2015"},{"key":"B34","volume-title":"The Ketamine Papers","author":"Wolfson","year":"2016"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.868103","article-title":"Toward synergies of ketamine and psychotherapy","volume":"13","author":"Mathai","year":"2022","journal-title":"Front Psychol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0078","article-title":"Parental attitudes toward use of ketamine in adolescent mood disorders and suicidality","volume":"31","author":"Mathai","year":"2021","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1433348","article-title":"Empowering understanding: navigating consent to ketamine treatment in adolescent mental health","volume":"15","author":"Sathappan","year":"2024","journal-title":"Front Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1485","article-title":"Informed consent in decision-making in pediatric practice","volume":"138","author":"Katz","year":"2016","journal-title":"Pediatrics"},{"key":"B39","volume-title":"Ethical Conduct of Clinical Research Involving Children","author":"Field","year":"2004"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1007\/164_2018_148","article-title":"1,2-Diarylethylamine- and ketamine-based new psychoactive substances","volume-title":"New Psychoactive Substances","author":"Wallach","year":"2018"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06204-3","article-title":"Psychedelics reopen the social reward learning critical period","volume":"618","author":"Nardou","year":"2023","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6459","article-title":"Does general anesthesia affect neurodevelopment in infants and children","volume":"367","author":"McCann","year":"2019","journal-title":"BMJ"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(99)80051-1","article-title":"Inadvertent ketamine overdose in children: clinical manifestations and outcome","volume":"34","author":"Green","year":"1999","journal-title":"Ann Emerg Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31825ae442","article-title":"Neurotoxicity of ketamine: known unknowns","volume":"40","author":"Soriano","year":"2012","journal-title":"Crit Care Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfm084","article-title":"Ketamine-induced neuronal cell death in the perinatal rhesus monkey","volume":"98","author":"Slikker","year":"2007","journal-title":"Toxicol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9375910","article-title":"Case report of subanesthetic intravenous ketamine infusion for the treatment of neuropathic pain and depression with suicidal features in a pediatric patient","volume":"2018","author":"Weber","year":"2018","journal-title":"Case Rep Anesthesiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/pan.13203","article-title":"Interventions for postoperative pain in children: an overview of systematic reviews","volume":"27","author":"Boric","year":"2017","journal-title":"Paediatr Anaesth."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.05.094","article-title":"Intranasal ketamine for acute pain management in children: a systematic review and meta-analysis","volume":"38","author":"Oliveira J E Silva","year":"2020","journal-title":"Am J Emerg Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(72)90774-0","article-title":"Study of ketamine as an obstetric anesthetic agent","volume":"113","author":"Little","year":"1972","journal-title":"Am J Obstet. Gynecol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.expneurol.2015.03.028","article-title":"Neurodevelopmental implications of the general anesthesia in neonate and infants","volume":"272","author":"Lee","year":"2015","journal-title":"Exp Neurol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/ANA.0000000000000027","article-title":"Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain","volume":"26","author":"Yan","year":"2014","journal-title":"J Neurosurg Anesthesiol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.1061","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review","volume":"8","author":"Walsh","year":"2022","journal-title":"BJPsych. Open"},{"key":"B56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jad.2022.07.004","article-title":"At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial","volume":"314","author":"Hull","year":"2022","journal-title":"J Affect Disord"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.992624","article-title":"Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: a retrospective study of off-label, at-home use","volume":"13","author":"Hassan","year":"2022","journal-title":"Front Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest package: tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J Stat Softw."},{"key":"B60","article-title":"merTools: tools for analyzing mixed effect regression models","volume-title":"R Package Version 0.5.2. CRAN.","author":"Knowles","year":"2016"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1467-9868.2010.00749.x","article-title":"Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models","volume":"73","author":"Wood","year":"2011","journal-title":"J R. Stat Soc Ser B. Stat Methodol."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989x.1.2.170","article-title":"Meta-analysis of experiments with matched groups or repeated measures designs","volume":"1","author":"Dunlap","year":"1996","journal-title":"Psychol Methods"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989x.7.1.105","article-title":"Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs","volume":"7","author":"Morris","year":"2002","journal-title":"Psychol Methods"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front Psychol"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.4324\/9780203771587","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"B66","volume-title":"R: A Language and Environment for Statistical Computing","year":"2025"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1886833\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:17:59Z","timestamp":1789982279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1886833\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":66,"alternative-id":["10.3389\/fpsyt.2026.1886833"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1886833","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1886833"}}